Diagnostic pathways in multiple myeloma and their relationship to end organ damage: an analysis from the Tackling Early Morbidity and Mortality in Myeloma (TEAMM) trial
Catherine Atkin(University of Birmingham), Janet Dunn(National Health Service), Kerry Raynes(University of Warwick), Helen Higgins(University of Warwick), Mark T. Drayson(University of Birmingham), Guy Pratt(Heart of England NHS Foundation Trust), Kwee Yong(London Cancer), Richard D Neal(Bangor University), Gulnaz Iqbal(University of Warwick), Stella Bowcock(King's College Hospital), Eric Low(RED Consulting (Norway)), Tim Planche(Leeds Teaching Hospitals NHS Trust), Jill Wood(University of Warwick)
Cited by 9
Related Papers
High-Dose Chemotherapy with Hematopoietic Stem-Cell Rescue for Multiple Myeloma
|New England Journal of Medicine|2003|1.8k
Cilta-cel or Standard Care in Lenalidomide-Refractory Multiple Myeloma
|New England Journal of Medicine|2023|719
Docetaxel versus active symptom control for refractory oesophagogastric adenocarcinoma (COUGAR-02): an open-label, phase 3 randomised controlled trial
|The Lancet Oncology|2013|604
First-line treatment with zoledronic acid as compared with clodronic acid in multiple myeloma (MRC Myeloma IX): a randomised controlled trial
|The Lancet|2010|571
Mutational Spectrum, Copy Number Changes, and Outcome: Results of a Sequencing Study of Patients With Newly Diagnosed Myeloma
|Journal of Clinical Oncology|2015|564